补中益气汤加减对非小细胞肺癌化疗后骨髓抑制患者免疫功能的影响及疗效观察
收稿日期: 2025-09-29
修回日期: 2026-01-12
录用日期: 2026-03-18
网络出版日期: 2026-10-27
基金资助
河北省中医药管理局科研计划项目(20203602105)
Effect of Modified Buzhong Yiqi Decoction on Immune Function and Treatment Efficacy in Patients with Bone Marrow Suppression After Chemotherapy for Non-small Cell Lung Cancer
Received date: 2025-09-29
Revised date: 2026-01-12
Accepted date: 2026-03-18
Online published: 2026-10-27
目的:分析补中益气汤加减对非小细胞肺癌(NSCLC)化疗后骨髓抑制患者免疫功能的影响。方法:选取2022年5月至2024年2月123例NSCLC术后化疗患者的临床资料,依据治疗方式不同进行分组,化疗组采用常规化疗治疗(n=61例),中医组在上述基础上予以补中益气汤加减治疗(n=62例),分析两组临床疗效、T淋巴细胞亚群(CD4+、CD4+/CD8+)、免疫球蛋白G(IgG)、基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)、基质金属蛋白酶-1(MMP-1)水平及不良反应发生率。结果:治疗前,各组免疫功能指标相比无差异(P>0.05),治疗后,中医组IgG、CD4+、CD4+/CD8+、CD3+、NK均高于化疗组(P<0.05);治疗前,各组血清指标相比无差异(P>0.05),治疗后,中医组MMP-9、VEGF、MMP-1均较化疗组更低(P<0.05);中医组不良反应总发生率为14.52%,明显低于化疗组的34.43%(P<0.05)。结论:NSCLC化疗后应用补中益气汤加减治疗效果显著,分析其作用机制,该方可提升患者的CD3+、CD4+、CD4+/CD8+、NK细胞及IgG水平,降低MMP-9、VEGF、MMP-1水平;同时,可降低骨髓抑制等相关不良反应的发生率,安全性较高。
刘存斌
,
陈龙
,
郑军
,
陈超
.
补中益气汤加减对非小细胞肺癌化疗后骨髓抑制患者免疫功能的影响及疗效观察
Objective: To analyze the effect of Buzhong Yiqi Tang plus reduction on the immune function of patients with bone marrow suppression after chemotherapy for non-small cell lung cancer (NSCLC). Methods: The clinical data of 123 patients with NSCLC postoperative chemotherapy were retrospectively selected from May 2022 to February 2024, and grouped according to the different treatment modalities: the conventional chemotherapy group was treated with conventional chemotherapy (n=61 patients), and the Chinese medicine group was treated with tonic Chinese medicine and Yiqi soup plus or minus on the basis of the above treatment (n=62 patients), and the clinical efficacy and the effect of T The clinical efficacy, T-lymphocyte subpopulations (CD4+, CD4+/CD8+), immunoglobulin G (IgG), matrix metalloproteinase-9 (MMP-9), vascular endothelial growth factor (VEGF), matrix metalloproteinase-1 (MMP-1) levels, and the incidence rate of adverse reactions were analyzed. Results: There was no difference in the immune function indexes of the groups before treatment (P>0.05), and the IgG, CD4+, and CD4+/CD8+ in the TCM group were higher than those of the conventional chemotherapy group (P<0.05); there was no difference in serum indexes of the groups before treatment (P>0.05), and there was no difference in serum indexes of the groups after treatment (P<0.05). 0.05), MMP-9, VEGF, MMP-1 in the TCM group were lower than those in the conventional chemotherapy group after treatment (P<0.05); the total incidence rate of adverse reactions in the TCM group was 14.52%, which was significantly lower than that of 34.43% in the conventional chemotherapy group (P<0.05). Conclusion: The application of Buzhong Yiqi Tang with modifications following chemotherapy for NSCLC demonstrates significant therapeutic efficacy. Mechanistically, it enhances patients' CD3+, CD4+, CD4+/CD8+, NK cell, and IgG levels while reducing MMP-9, VEGF, and MMP-1 levels. Clinically. it lowers the incidence of adverse reactions such as bone marrow suppression and exhibits high safety.
[1] 肿瘤医学论坛.2020年全球癌症最新数据解读[J].中国肿瘤临床与康复,2021,28(3):301.
[2] 中华医学会病理学分会工作组,北京病理学会工作组,刘东戈,等.非小细胞肺癌细胞学标本上清液驱动基因规范化检测指南(2023年版)[J].中国肿瘤临床与康复,2023,30(7):397-405.
[3] 孔文杰,李宝亮,邹芳,等.老年非小细胞肺癌放化疗患者下呼吸道感染病原菌分布及危险因素分析[J].传染病信息,2024,37(1):61-64,69.
[4] 王宁,李刚,龚胜,等.非小细胞肺癌合并HIV感染/AIDS手术患者病理和临床特征及术后并发症影响因素分析[J].新发传染病电子杂志,2024,9(2):29-33.
[5] 温钧涵,慕岳峻,刘歆,等.中医药联合免疫检查点抑制剂在晚期非小细胞肺癌治疗中的探索[J].中医药学报,2024,52(3):80-86.
[6] 龙飞,王欣,赵培佑,等.李世杰运用健脾益肾、补气养血法治疗化疗后骨髓抑制经验[J].湖南中医杂志,2018,31(3):31-32.
[7] 陈志红,王晞星,杨丽芳.王晞星运用补中益气汤治疗肿瘤相关疾病思路与经验[J].新中医,2021,53(19):160-163.
[8] 中国常见恶性肿瘤诊治规范[M].北京:北京医科大学/中国协和医科大学联合出版社,1991:1-2.
[9] 王永,解华,李凌云.贝伐珠单抗联合厄洛替尼对晚期非小细胞肺癌患者疗效、血清CYFRA21-1水平及KPS评分的影响[J].临床和实验医学杂志,2021,20(8):827-830.
[10] 中医病证诊断疗效标准编审委员会.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:86.
[11] 于建平,刘戴维,耿艳琴.五禽戏鸟戏联合基于中医辨证的中医适宜技术对非小细胞肺癌化疗患者胃肠道及免疫功能的影响[J].河北中医,2024,46(5):821-824,828.
[12] 苏振邦,易良杰.基于数据挖掘分析中医联合化疗治疗非小细胞肺癌用药规律[J].云南中医中药杂志,2024,45(4):31-36.
[13] Raimondos S, Puccini L, Alessandri C, et al. Extracellular vesicles and tumor-immune escape: biological functions and clinical perspectives[J]. Int J Mol Sci, 2020,21(7):2286.
[14] 应笑丽,杨晓晨,许海阳,等.补中益气汤对ICU术后化疗患者免疫功能的影响[J].中国现代医生,2022,60(17):171-174.
[15] 麦柳芳.补中益气汤联合化疗治疗胃癌术后随机平行对照研究[J].实用中医内科杂志,2019,33(1):36-39.
[16] 孙玉彰,李北平,陈良.补中益气汤加减治疗胃癌术后化疗脾胃气虚证患者的临床观察[J].世界中西医结合杂志,2021,16(12):2308-2313,2319.
[17] 吴娇,郝腾腾,李刘生,等.吴煜运用补中益气汤合二陈汤加减治疗癌痛[J].辽宁中医杂志,2021,48(11):46-49.
[18] 张诗杭,刘斯瑀,罗燕.基于药用衡制探讨补中益气汤原方对应的现代剂量[J].中国民族民间医药,2021,30(23):16-18,44.
[19] Bowers SLK, Kemp SS, Aguera KN, et al. Defining an upstream VEGF (vascular endothelial growth factor) priming signature for downstream factor-Induced endothelial cell-pericyte tube network coassembly[J].Arterioscler Thromb Vasc Biol. 2020, 40(12):2891-2909.
[20] 罗文,王涛,熊国江,等.补中益气汤加减对非小细胞肺癌术后化疗患者VEGF,IGF-1,TGF-β1,免疫功能的影响及安全性分析[J].中国实验方剂学杂志,2021,27(16):90-95.
[21] 葛玲玲,曹芳.补中益气汤治疗肿瘤的现代应用[J].山东中医药大学学报,2019,42(4):367-369.
/
| 〈 |
|
〉 |